Effects of olanzapine and clozapine upon pulse rate variability

Michael Mueck-Weymann, Thomas Rechlin, Franz Ehrengut, Robert Rauh, Jens Acker, Ralf W. Dittmann, Jörg Czekalla, Peter Joraschky, Dominique Musselman

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Based upon their in vitro receptor binding profiles, the atypical antipsychotics clozapine and olanzapine exhibit cholinergic receptor binding of similar potency. Data comparing the in vivo anticholinergic effects, however, of these neuroleptics upon neurocardiac control are sparse. The goal of this study was to compare the in vivo effects of clozapine and olanzapine upon neurocardiac control by assessment of the pulse rate variability (PRV) in schizophrenic patients and healthy controls. Twenty patients with schizophrenia (according to DSM-III-R criteria) treated with either clozapine (100-600 mg/day) or olanzapine (10-20 mg/day), and ten healthy controls, were recruited into the study. PRV was assessed by continuously recording the skin blood volume in the fingertip of the second digit under resting conditions and PRV parameters were calculated. When significant differences in PRV parameters between the patients and controls were detected by Kruskal-Wallis tests, Mann-Whitney tests were used to test for group differences between the olanzapine- and clozapine-treated patients. In comparison to the healthy controls, the PRV parameters of the clozapine- and olanzapine-treated schizophrenic patients were significantly reduced. Indeed the reduction of PRV was significantly greater in the clozapine-treated group compared to the olanzapine-treated group (P<0.05). Compared to the controls, only the clozapine-treated patients showed a significantly diminished low-frequency (LF)/high frequency (HF)-ratio, a PRV parameter reflecting sympatho-vagal balance. The significantly greater reductions in PRV parameters of the clozapine-treated compared to olanzapine-treated patients may be caused by clozapine's higher affinity for α1-adrenergic receptors in vivo compared with olanzapine. The similar LF/HF ratios of the healthy controls and olanzapine-treated patients suggests that the sympathetic-parasympathetic modulation of PRV remains relatively unchanged even during olanzapine treatment.

Original languageEnglish
Pages (from-to)93-99
Number of pages7
JournalDepression and Anxiety
Volume16
Issue number3
DOIs
StatePublished - Jan 1 2002
Externally publishedYes

Fingerprint

olanzapine
Clozapine
Heart Rate
Antipsychotic Agents
Cholinergic Antagonists
Cholinergic Receptors

Keywords

  • Atypical antipsychotics
  • Autonomic neuropathy
  • Clozapine
  • Heart rate variability
  • Neurocardiac control
  • Olanzapine
  • Pulse rate variability

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Mueck-Weymann, M., Rechlin, T., Ehrengut, F., Rauh, R., Acker, J., Dittmann, R. W., ... Musselman, D. (2002). Effects of olanzapine and clozapine upon pulse rate variability. Depression and Anxiety, 16(3), 93-99. https://doi.org/10.1002/da.10037

Effects of olanzapine and clozapine upon pulse rate variability. / Mueck-Weymann, Michael; Rechlin, Thomas; Ehrengut, Franz; Rauh, Robert; Acker, Jens; Dittmann, Ralf W.; Czekalla, Jörg; Joraschky, Peter; Musselman, Dominique.

In: Depression and Anxiety, Vol. 16, No. 3, 01.01.2002, p. 93-99.

Research output: Contribution to journalArticle

Mueck-Weymann, M, Rechlin, T, Ehrengut, F, Rauh, R, Acker, J, Dittmann, RW, Czekalla, J, Joraschky, P & Musselman, D 2002, 'Effects of olanzapine and clozapine upon pulse rate variability', Depression and Anxiety, vol. 16, no. 3, pp. 93-99. https://doi.org/10.1002/da.10037
Mueck-Weymann M, Rechlin T, Ehrengut F, Rauh R, Acker J, Dittmann RW et al. Effects of olanzapine and clozapine upon pulse rate variability. Depression and Anxiety. 2002 Jan 1;16(3):93-99. https://doi.org/10.1002/da.10037
Mueck-Weymann, Michael ; Rechlin, Thomas ; Ehrengut, Franz ; Rauh, Robert ; Acker, Jens ; Dittmann, Ralf W. ; Czekalla, Jörg ; Joraschky, Peter ; Musselman, Dominique. / Effects of olanzapine and clozapine upon pulse rate variability. In: Depression and Anxiety. 2002 ; Vol. 16, No. 3. pp. 93-99.
@article{ed6a23161f2049e5b39f3d3acbd5b39d,
title = "Effects of olanzapine and clozapine upon pulse rate variability",
abstract = "Based upon their in vitro receptor binding profiles, the atypical antipsychotics clozapine and olanzapine exhibit cholinergic receptor binding of similar potency. Data comparing the in vivo anticholinergic effects, however, of these neuroleptics upon neurocardiac control are sparse. The goal of this study was to compare the in vivo effects of clozapine and olanzapine upon neurocardiac control by assessment of the pulse rate variability (PRV) in schizophrenic patients and healthy controls. Twenty patients with schizophrenia (according to DSM-III-R criteria) treated with either clozapine (100-600 mg/day) or olanzapine (10-20 mg/day), and ten healthy controls, were recruited into the study. PRV was assessed by continuously recording the skin blood volume in the fingertip of the second digit under resting conditions and PRV parameters were calculated. When significant differences in PRV parameters between the patients and controls were detected by Kruskal-Wallis tests, Mann-Whitney tests were used to test for group differences between the olanzapine- and clozapine-treated patients. In comparison to the healthy controls, the PRV parameters of the clozapine- and olanzapine-treated schizophrenic patients were significantly reduced. Indeed the reduction of PRV was significantly greater in the clozapine-treated group compared to the olanzapine-treated group (P<0.05). Compared to the controls, only the clozapine-treated patients showed a significantly diminished low-frequency (LF)/high frequency (HF)-ratio, a PRV parameter reflecting sympatho-vagal balance. The significantly greater reductions in PRV parameters of the clozapine-treated compared to olanzapine-treated patients may be caused by clozapine's higher affinity for α1-adrenergic receptors in vivo compared with olanzapine. The similar LF/HF ratios of the healthy controls and olanzapine-treated patients suggests that the sympathetic-parasympathetic modulation of PRV remains relatively unchanged even during olanzapine treatment.",
keywords = "Atypical antipsychotics, Autonomic neuropathy, Clozapine, Heart rate variability, Neurocardiac control, Olanzapine, Pulse rate variability",
author = "Michael Mueck-Weymann and Thomas Rechlin and Franz Ehrengut and Robert Rauh and Jens Acker and Dittmann, {Ralf W.} and J{\"o}rg Czekalla and Peter Joraschky and Dominique Musselman",
year = "2002",
month = "1",
day = "1",
doi = "10.1002/da.10037",
language = "English",
volume = "16",
pages = "93--99",
journal = "Depression and Anxiety",
issn = "1091-4269",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Effects of olanzapine and clozapine upon pulse rate variability

AU - Mueck-Weymann, Michael

AU - Rechlin, Thomas

AU - Ehrengut, Franz

AU - Rauh, Robert

AU - Acker, Jens

AU - Dittmann, Ralf W.

AU - Czekalla, Jörg

AU - Joraschky, Peter

AU - Musselman, Dominique

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Based upon their in vitro receptor binding profiles, the atypical antipsychotics clozapine and olanzapine exhibit cholinergic receptor binding of similar potency. Data comparing the in vivo anticholinergic effects, however, of these neuroleptics upon neurocardiac control are sparse. The goal of this study was to compare the in vivo effects of clozapine and olanzapine upon neurocardiac control by assessment of the pulse rate variability (PRV) in schizophrenic patients and healthy controls. Twenty patients with schizophrenia (according to DSM-III-R criteria) treated with either clozapine (100-600 mg/day) or olanzapine (10-20 mg/day), and ten healthy controls, were recruited into the study. PRV was assessed by continuously recording the skin blood volume in the fingertip of the second digit under resting conditions and PRV parameters were calculated. When significant differences in PRV parameters between the patients and controls were detected by Kruskal-Wallis tests, Mann-Whitney tests were used to test for group differences between the olanzapine- and clozapine-treated patients. In comparison to the healthy controls, the PRV parameters of the clozapine- and olanzapine-treated schizophrenic patients were significantly reduced. Indeed the reduction of PRV was significantly greater in the clozapine-treated group compared to the olanzapine-treated group (P<0.05). Compared to the controls, only the clozapine-treated patients showed a significantly diminished low-frequency (LF)/high frequency (HF)-ratio, a PRV parameter reflecting sympatho-vagal balance. The significantly greater reductions in PRV parameters of the clozapine-treated compared to olanzapine-treated patients may be caused by clozapine's higher affinity for α1-adrenergic receptors in vivo compared with olanzapine. The similar LF/HF ratios of the healthy controls and olanzapine-treated patients suggests that the sympathetic-parasympathetic modulation of PRV remains relatively unchanged even during olanzapine treatment.

AB - Based upon their in vitro receptor binding profiles, the atypical antipsychotics clozapine and olanzapine exhibit cholinergic receptor binding of similar potency. Data comparing the in vivo anticholinergic effects, however, of these neuroleptics upon neurocardiac control are sparse. The goal of this study was to compare the in vivo effects of clozapine and olanzapine upon neurocardiac control by assessment of the pulse rate variability (PRV) in schizophrenic patients and healthy controls. Twenty patients with schizophrenia (according to DSM-III-R criteria) treated with either clozapine (100-600 mg/day) or olanzapine (10-20 mg/day), and ten healthy controls, were recruited into the study. PRV was assessed by continuously recording the skin blood volume in the fingertip of the second digit under resting conditions and PRV parameters were calculated. When significant differences in PRV parameters between the patients and controls were detected by Kruskal-Wallis tests, Mann-Whitney tests were used to test for group differences between the olanzapine- and clozapine-treated patients. In comparison to the healthy controls, the PRV parameters of the clozapine- and olanzapine-treated schizophrenic patients were significantly reduced. Indeed the reduction of PRV was significantly greater in the clozapine-treated group compared to the olanzapine-treated group (P<0.05). Compared to the controls, only the clozapine-treated patients showed a significantly diminished low-frequency (LF)/high frequency (HF)-ratio, a PRV parameter reflecting sympatho-vagal balance. The significantly greater reductions in PRV parameters of the clozapine-treated compared to olanzapine-treated patients may be caused by clozapine's higher affinity for α1-adrenergic receptors in vivo compared with olanzapine. The similar LF/HF ratios of the healthy controls and olanzapine-treated patients suggests that the sympathetic-parasympathetic modulation of PRV remains relatively unchanged even during olanzapine treatment.

KW - Atypical antipsychotics

KW - Autonomic neuropathy

KW - Clozapine

KW - Heart rate variability

KW - Neurocardiac control

KW - Olanzapine

KW - Pulse rate variability

UR - http://www.scopus.com/inward/record.url?scp=0036428523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036428523&partnerID=8YFLogxK

U2 - 10.1002/da.10037

DO - 10.1002/da.10037

M3 - Article

C2 - 12415532

AN - SCOPUS:0036428523

VL - 16

SP - 93

EP - 99

JO - Depression and Anxiety

JF - Depression and Anxiety

SN - 1091-4269

IS - 3

ER -